Hanson Gifford of The Foundry reviews the evolving challenges behind Medtech innovation and shares details on Fire1 and Ardian.
Hanson S. Gifford III
Since 1998, Mr. Gifford has been a Managing Member of The Foundry, LLC. Its activities include the invention, identification and development of new technologies, and the formation, financing, and staffing of new companies. The Foundry has created Evalve (acquired by Abbott Labs), Concentric Medical (acquired by Stryker), Emphasys Medical, First to File, Satiety, Xtent (Nasdaq:XTNT), Cierra Medical, Ardian (acquired by Medtronic), Cabochon (acquired by Ulthera/Merz), Miramar Labs, Twelve, Holaira, Cotera, and Fire1. Mr. Gifford is also a founder of ForSight Labs, an ophthalmic device incubator which has started six companies.
Prior to The Foundry, Mr. Gifford was VP of Research and Development at Heartport, Inc. (Nasdaq:HPRT) from 1993-1998. In 1992, Mr. Gifford was co-founder and managing director of Bavaria Medizin Technologie (BMT) GmbH. In 1991, Mr. Gifford served as President of CTT (acquired by Eli Lilly). From 1985-1990, Mr. Gifford worked at Devices for Vascular Intervention (acquired by Eli Lilly).
Mr. Gifford is an inventor on over 225 issued US patents. He has a BSME from Cornell.
Meet Our Host
Geoff has been in medtech for over two decades in both operational and investment roles. He is passionate about the industry potential and sharing stories from the front lines of innovation.